JP2017101068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017101068A5 JP2017101068A5 JP2017037131A JP2017037131A JP2017101068A5 JP 2017101068 A5 JP2017101068 A5 JP 2017101068A5 JP 2017037131 A JP2017037131 A JP 2017037131A JP 2017037131 A JP2017037131 A JP 2017037131A JP 2017101068 A5 JP2017101068 A5 JP 2017101068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- alk1
- fusion protein
- preparation according
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5016808P | 2008-05-02 | 2008-05-02 | |
| US61/050,168 | 2008-05-02 | ||
| US14413109P | 2009-01-12 | 2009-01-12 | |
| US61/144,131 | 2009-01-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237666A Division JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019171838A Division JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017101068A JP2017101068A (ja) | 2017-06-08 |
| JP2017101068A5 true JP2017101068A5 (enExample) | 2018-02-22 |
Family
ID=41055305
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507463A Expired - Fee Related JP5719766B2 (ja) | 2008-05-02 | 2009-05-01 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2014237666A Expired - Fee Related JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2017037131A Withdrawn JP2017101068A (ja) | 2008-05-02 | 2017-02-28 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2019171838A Withdrawn JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2021144016A Pending JP2021183652A (ja) | 2008-05-02 | 2021-09-03 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507463A Expired - Fee Related JP5719766B2 (ja) | 2008-05-02 | 2009-05-01 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2014237666A Expired - Fee Related JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019171838A Withdrawn JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2021144016A Pending JP2021183652A (ja) | 2008-05-02 | 2021-09-03 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8158584B2 (enExample) |
| EP (2) | EP3398966A1 (enExample) |
| JP (5) | JP5719766B2 (enExample) |
| KR (8) | KR20210014224A (enExample) |
| CN (2) | CN105963695A (enExample) |
| AU (5) | AU2009241755B2 (enExample) |
| BR (1) | BRPI0911853A8 (enExample) |
| CA (1) | CA2723449C (enExample) |
| MX (2) | MX391905B (enExample) |
| TW (3) | TW201609138A (enExample) |
| WO (1) | WO2009134428A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10059756B2 (en) * | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| KR20170012582A (ko) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| CL2008003302A1 (es) | 2007-11-09 | 2009-03-06 | Genentech Inc | Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos. |
| CN105963695A (zh) * | 2008-05-02 | 2016-09-28 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
| EP2291401A2 (en) * | 2008-05-15 | 2011-03-09 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| WO2013116781A1 (en) * | 2012-02-02 | 2013-08-08 | Acceleron Pharma Inc. | Alk1 antagonists and their uses in treating renal cell carcinoma |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| HK1225742A1 (zh) * | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| EP3280435B1 (en) * | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| CN110317264B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物 |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| AU2018358804A1 (en) * | 2017-11-02 | 2020-04-09 | Bayer Aktiengesellschaft | Bispecific antibodies binding ALK-1 and BMPR-2 |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| CN114028541A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | Gdf2在制备改善肿瘤异常血管的药物中的用途 |
| CN121079328A (zh) * | 2023-01-18 | 2025-12-05 | 开拓药业(广东)有限公司 | 抗alk-1抗体及其用途 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| JPH08504577A (ja) | 1992-10-30 | 1996-05-21 | エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ | ＴＧＦ−βの制御活性を改変するための組成物および方法 |
| US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| NZ257631A (en) | 1992-11-17 | 1996-03-26 | Ludwig Inst Cancer Res | Serine/threonine kinase domain-containing protein, dna and hosts therefor |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| JP2000514777A (ja) | 1995-08-14 | 2000-11-07 | クリエイティブ バイオモレキュールズ，インコーポレイテッド | 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合 |
| US6190660B1 (en) | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| EP0938505B1 (en) | 1996-05-31 | 2002-03-06 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy |
| MX9701946A (es) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| EP1071765A4 (en) | 1998-03-13 | 2003-01-15 | Ludwig Inst Cancer Res | Alk-1 responds to tgf-beta and signals through smad-1 and smad-5 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US20030012792A1 (en) | 1998-05-22 | 2003-01-16 | Holaday John W. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US7077836B2 (en) | 2000-07-21 | 2006-07-18 | Vein Rx, Inc. | Methods and apparatus for sclerosing the wall of a varicose vein |
| CA2417982A1 (en) | 2000-08-03 | 2002-02-14 | The University Of Utah Research Foundation | Manipulation of arterial-venous identity |
| DE10043481A1 (de) | 2000-09-04 | 2002-04-11 | Vectron Therapeutics Ag Imt | Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung |
| CN1966725A (zh) | 2001-10-31 | 2007-05-23 | 爱尔康公司 | 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| WO2003064628A2 (en) | 2002-02-01 | 2003-08-07 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| CA2484994C (en) | 2002-04-29 | 2016-06-14 | St. Louis University | Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
| WO2004003163A2 (en) | 2002-06-27 | 2004-01-08 | University Of Utah Research Foundation | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| AU2003287444A1 (en) | 2002-10-31 | 2004-05-25 | The General Hospital Corporation | Repairing or replacing tissues or organs |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| WO2005044849A2 (en) | 2003-08-05 | 2005-05-19 | Eli Lilly And Company | Lp mammalian proteins; related reagents |
| CA2554703A1 (en) | 2004-01-27 | 2005-12-08 | Compugen Ltd. | Differential expression of markers in ovarian cancer |
| US7101618B2 (en) * | 2004-05-07 | 2006-09-05 | 3M Innovative Properties Company | Article comprising fluorochemical surface layer |
| WO2005113590A2 (en) * | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| WO2006091930A2 (en) | 2005-02-24 | 2006-08-31 | Massachusetts Eye & Ear Infirmary | Methods and compounds for promoting vessel regression |
| SI2447283T1 (sl) | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc. | Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1) |
| WO2007143023A1 (en) | 2006-05-31 | 2007-12-13 | Beth Israel Deaconess Medical Center | Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer |
| US10059756B2 (en) * | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| KR20170012582A (ko) * | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| CL2008003302A1 (es) * | 2007-11-09 | 2009-03-06 | Genentech Inc | Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos. |
| CN105963695A (zh) * | 2008-05-02 | 2016-09-28 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
| EP2291401A2 (en) * | 2008-05-15 | 2011-03-09 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
-
2009
- 2009-05-01 CN CN201610297436.0A patent/CN105963695A/zh active Pending
- 2009-05-01 EP EP18154273.9A patent/EP3398966A1/en active Pending
- 2009-05-01 MX MX2017011333A patent/MX391905B/es unknown
- 2009-05-01 MX MX2010011998A patent/MX2010011998A/es active IP Right Grant
- 2009-05-01 TW TW104119480A patent/TW201609138A/zh unknown
- 2009-05-01 US US12/434,598 patent/US8158584B2/en active Active
- 2009-05-01 KR KR1020217003129A patent/KR20210014224A/ko not_active Withdrawn
- 2009-05-01 CA CA2723449A patent/CA2723449C/en active Active
- 2009-05-01 KR KR1020107027046A patent/KR20110031908A/ko not_active Ceased
- 2009-05-01 KR KR1020187006926A patent/KR20180029111A/ko not_active Ceased
- 2009-05-01 KR KR1020217028926A patent/KR20210113446A/ko not_active Ceased
- 2009-05-01 KR KR1020197032900A patent/KR20190128254A/ko not_active Withdrawn
- 2009-05-01 KR KR1020197008836A patent/KR20190037355A/ko not_active Withdrawn
- 2009-05-01 WO PCT/US2009/002699 patent/WO2009134428A2/en not_active Ceased
- 2009-05-01 EP EP09739231A patent/EP2283040A2/en not_active Withdrawn
- 2009-05-01 KR KR1020207018412A patent/KR20200079567A/ko not_active Withdrawn
- 2009-05-01 KR KR1020177002063A patent/KR20170012595A/ko not_active Ceased
- 2009-05-01 AU AU2009241755A patent/AU2009241755B2/en not_active Ceased
- 2009-05-01 BR BRPI0911853A patent/BRPI0911853A8/pt not_active IP Right Cessation
- 2009-05-01 TW TW106106131A patent/TWI672151B/zh not_active IP Right Cessation
- 2009-05-01 JP JP2011507463A patent/JP5719766B2/ja not_active Expired - Fee Related
- 2009-05-01 TW TW098114652A patent/TWI586364B/zh not_active IP Right Cessation
- 2009-05-01 CN CN200980125712.3A patent/CN102099374B/zh not_active Expired - Fee Related
-
2012
- 2012-04-13 US US13/447,077 patent/US20130039910A1/en not_active Abandoned
-
2014
- 2014-11-25 JP JP2014237666A patent/JP6194302B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-04 AU AU2016200018A patent/AU2016200018A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017037131A patent/JP2017101068A/ja not_active Withdrawn
-
2018
- 2018-01-11 AU AU2018200237A patent/AU2018200237B2/en not_active Ceased
- 2018-02-13 US US15/895,894 patent/US20180179293A1/en not_active Abandoned
-
2019
- 2019-09-18 AU AU2019232838A patent/AU2019232838B2/en not_active Ceased
- 2019-09-20 JP JP2019171838A patent/JP2019210298A/ja not_active Withdrawn
-
2021
- 2021-01-04 US US17/140,398 patent/US20210388104A1/en not_active Abandoned
- 2021-09-03 JP JP2021144016A patent/JP2021183652A/ja active Pending
- 2021-12-13 AU AU2021286240A patent/AU2021286240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| US20210115150A1 (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| ES2808153T3 (es) | Terapia de combinación para tratamiento de enfermedad | |
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| US20170002060A1 (en) | Polynucleotides for the in vivo production of antibodies | |
| JP2011520793A5 (enExample) | ||
| EP3092250A1 (en) | Polynucleotides for the in vivo production of antibodies | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2012529436A5 (enExample) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| BR112016002614B1 (pt) | Imunocitoquina e composição farmacêutica | |
| JP2022511286A (ja) | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 | |
| JP6907229B2 (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| JP7048567B2 (ja) | 二重特異性抗原結合ポリペプチド | |
| WO2016180034A1 (zh) | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 | |
| ES2966030T3 (es) | Anticuerpos anti-VEGFR-2/KDR humanos | |
| US20230235073A1 (en) | Anti-cd36 antibodies and their use to treat cancer | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP2021505183A (ja) | ヒトｉｌ−５に結合するモノクローナル抗体、その製造方法および用途 | |
| JP2018529661A5 (enExample) | ||
| CA3168923A1 (en) | Combination therapy for treatment of cancer and cancer metastasis | |
| Markatseli et al. | Certolizumab for rheumatoid arthritis | |
| JP2017513857A (ja) | Ｃｄ１４７に結合する抗体医薬 | |
| CN116262790A (zh) | 嵌合的抗cd27抗体组合物及其应用 | |
| EP2125895A2 (en) | Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis |